|1.||Targan, Stephan R: 3 articles (11/2010 - 04/2009)|
|2.||Baumgart, Daniel C: 3 articles (11/2010 - 04/2009)|
|3.||Mayer, Lloyd: 3 articles (11/2010 - 11/2007)|
|4.||Sandborn, William J: 3 articles (11/2010 - 04/2009)|
|5.||Lowder, James N: 3 articles (11/2010 - 04/2009)|
|6.||Van Assche, Gert: 2 articles (11/2010 - 11/2007)|
|7.||Plevy, Scott: 2 articles (11/2010 - 11/2007)|
|8.||Frankel, Matthew: 2 articles (11/2010 - 11/2007)|
|9.||Frankel, Matthew B: 2 articles (04/2010 - 04/2009)|
|10.||Mahadevan, Uma: 2 articles (04/2010 - 11/2007)|
11/01/2007 - "Visilizumab had an acceptable safety profile at the 10-microg/kg dose level and may be clinically beneficial in patients with severe intravenous corticosteroid-refractory ulcerative colitis."
11/01/2010 - "Pilot studies with visilizumab, a humanised monoclonal antibody to CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). "
11/01/2007 - "A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis."
01/01/2011 - "IBD: Visilizumab not useful for intravenous steroid-refractory ulcerative colitis."
11/01/2010 - "Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis."
|2.||Graft vs Host Disease (Graft-Versus-Host Disease)
04/15/2002 - "To test pharmacokinetics, safety, and immunosuppressive activity of visilizumab, 17 patients with glucocorticoid-refractory acute graft-versus-host disease (GVHD) were enrolled in a phase 1 study. "
06/01/2005 - "A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease."
04/15/2002 - "A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease."
06/01/2005 - "Results of a previous phase I study suggested that a single 3 mg/m2 dose of the humanized non-FcR-binding anti-CD3 monoclonal antibody visilizumab (Nuvion) was well tolerated and had efficacy for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). "
|3.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/01/2012 - "Similarly, encouraging results from phase 1/2 clinical trials have been reported for visilizumab and foralumab in patients with inflammatory bowel disease. "
06/01/2008 - "During the last decade, an increased understanding of the pathogenesis of inflammatory bowel disease has led to the rapid development of other biological agents, such as basiliximab and visilizumab. "
03/01/2002 - "Protein Design Labs Inc (PDL) is developing SMART anti-CD3 (Nuvion) as a potential therapeutic for autoimmune diseases such as inflammatory bowel disease (IBD), and as a prophylactic for transplant rejection. "
|3.||Fibroblast Growth Factor 7
|9.||acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamide
|2.||Nebulizers and Vaporizers (Inhaler)
|3.||Blood Component Removal (Apheresis)